Skip to Content

MD Anderson Events

Vemerafenib in Metastatic Melanoma

Vemerafenib in Metastatic Melanoma

  • Review common targeted  therapy treatment of metastatic melanoma
  • Identify pathology findings that indicate a patient is a candidate for BRAF inhibitors
  • Identify patients characteristics that indicate use of BRAF inhibitors
  • State toxicities of BRAF inhibitors and associated nursing interventions
  • Discuss how BRAF is used in combinations therapies

Date: 5/22/13, 7:30am to 8:30am
Time: 5/22/13, 7:30am to 8:30am
Location: R9 Melanoma Center Conference Room
Format: Training/Employee Development
CME: Contact Hours: 1.0
Speaker: Tina Dett, FNP
Contact: Cindy Murphy - 39297 - cmurphy@mdanderson.org